Efficacy and safety of KN026 and docetaxel for HER2‐positive breast cancer: a phase II clinical trial

Efficacy and safety of KN026 and docetaxel for HER2‐positive breast cancer: a phase II clinical trial

Abstract Background The standard first‐line treatment for human epidermal growth factor receptor 2 (HER2)‐positive recurrent/metastatic breast cancer currently includes pertuzumab plus trastuzumab and docetaxel. This study aimed to evaluate the effectiveness of KN026, an anti‐HER2 bispecific antibod...

Full description

Saved in:
Bibliographic Details
Main Authors: Jianli Ma, Jingxuan Wang, Ting Xu, Quchang Ouyang, Xiaojia Wang, Jingfen Wang, Lu Gan, Zhong Ouyang, Daren Lin, Tao Sun, Changping Shan, Herui Yao, Baochun Zhang, Zhengguang Li, Zhixiang Zhuang, Ying Lu, Hongwei Yang, Jian Huang, Xingwang Yang, Hongmei Sun, Qingyuan Zhang
Format: Article
Language:English
Published: Wiley 2025-04-01
Series:Cancer Communications
Subjects:
Breast Neoplasms
Antineoplastic Agents
anti‐HER‐2 Bispecific Antibody
Phase II Clinical Trial
Docetaxel
Online Access:https://doi.org/10.1002/cac2.12662
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/cac2.12662

Similar Items